Can-Fite BioPharma (CANF) – Investment Analysts’ Recent Ratings Updates

Can-Fite BioPharma (NYSE: CANF) has recently received a number of price target changes and ratings updates:

• 2/19/2025 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/18/2025 – Can-Fite BioPharma had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
• 2/11/2025 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/3/2025 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/26/2025 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/18/2025 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/10/2025 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/2/2025 – Can-Fite BioPharma is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 12/31/2024 – Can-Fite BioPharma had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.

Can-Fite BioPharma Stock Down 5.8 %

Shares of NYSE:CANF traded down $0.11 on Friday, reaching $1.80. The company had a trading volume of 217,206 shares, compared to its average volume of 111,553. The stock has a market capitalization of $5.66 million, a P/E ratio of -1.01 and a beta of 1.33. The stock has a 50-day moving average price of $1.54 and a 200 day moving average price of $1.98. Can-Fite BioPharma Ltd. has a twelve month low of $1.29 and a twelve month high of $4.69.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers lifted its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.